Micro RNAs as potential biomarkers in tuberculosis: A systematic review

Bijay Pattnaik, Niharika Patnaik, Saurabh Mittal, Anant Mohan, Anurag Agrawal, Randeep Guleria, Karan Madan

Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India
Centre of Excellence in Asthma & Lung Disease, Molecular Immunogenetics Lab, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India

ABSTRACT

Tuberculosis (TB) remains a major infectious disease across the globe. With increasing TB infections and a rise in multi-drug resistance, rapid diagnostic modalities are required to achieve TB control. Radiological investigations and microbiological tests (microscopic examination, cartridge-based nucleic acid amplification tests, and cultures) are most commonly used to diagnose TB. Histopathological/cytopathological examinations are also required for an accurate diagnosis in many patients.

The causative agent, Mycobacterium tuberculosis (Mtbc), is known to circumvent the host’s immune system. Circulating microRNAs (miRNAs) play a crucial role in biological pathways and can be used as a potential biomarker to detect tuberculosis. miRNAs are small non-coding RNAs and negatively regulate gene expression during post-transcriptional regulation. The differential expression of miRNAs in multiple clinical samples in tuberculosis patients may be helpful as potential disease biomarkers. This review summarizes the literature on miRNAs in various clinical samples as biomarkers for TB diagnosis.

1. Introduction

Due to tuberculosis, more than 1 million people die every year in low-income and middle-income countries [1]. According to current reports, one-third of the world population is latently infected with tuberculosis [2]. However, only 5–10% of infected people develop active tuberculosis in their lifetime [3]. The causative bacillus, i.e. Mycobacterium tuberculosis (Mtbc), commonly infects the respiratory system by inhalation and reaches the alveolar space [4]. Further, mycobacteria undergo phagocytosis by the alveolar macrophages and attribute to granuloma formation. Another report suggests that Mtbc can modulate cellular processes like cytokine production and phagolysosome maturation in macrophages and dendritic cells [5]. Understanding the pathogenesis is crucial to the success of tuberculosis control programs.

For TB control, accurate and rapid modalities for the initial diagnosis are required. However, the standard methods to detect tuberculosis involve the growth of microorganisms in a selective medium that requires 3–12 weeks [6]. Smear examinations are also used to detect tuberculosis, but sputum smears have low sensitivity [7]. Although the PCR and immunological tests based evaluation of tuberculosis are rapid diagnostic methods [8], false-positive and negative results make them unreliable. Other reliable diagnosis modalities include demonstrating granulomatous inflammation in the affected organs and a compatible clinico-radiological profile [9]. The various modalities for tissue sampling in intrathoracic TB include endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), bronchoalveolar lavage (BAL), endobronchial biopsy (EBB), transbronchial lung biopsy (TBLB), or percutaneous sampling modalities [10]. These are invasive diagnostic modalities that require super-speciality facilities and expertise. To improve non-invasive and early diagnosis, the global scientific community continuously researches new diagnostic modalities.

Accumulating evidence suggests that most of the cell-mediated immune responses are controlled by microRNAs (miRNAs), and the modulation of miRNA expression associated with these biological processes is one of the crucial strategies to prevent the spread of infection [11–16]. MiRNAs are small, single-stranded, non-coding RNAs that bind to the specific gene to modulate its expression [17,18]. These involve multiple cellular processes, such as cell cycle control, apoptosis, and several developmental and physiological processes [19]. Alteration of miRNAs expressions and gene expressions is associated with multiple respiratory diseases’ pathogenesis.

Several studies have suggested the role of circulating miRNAs in...
patients with pulmonary tuberculosis and identified miRNA signatures that could discriminate between patients with active tuberculosis and healthy controls or latent tuberculosis [20]. Currently, global TB research has focused on the importance of miRNAs in the pathogenesis of tuberculosis. Several researchers have explored the role of thousands of miRNA effects in pathogenesis and attempted to identify new biomarkers for diagnosing tuberculosis in different patients’ samples [20–22]. Given the importance of miRNAs as potential biomarkers for detecting tuberculosis, we have reviewed the literature on identifying miRNAs in different sample types and the role of the identified miRNAs in Mtb infected patients.

This review article summarizes recently discovered miRNAs isolated from different clinical samples in patients with tuberculosis. We have also highlighted their role in the pathogenesis of tuberculosis and their potential as TB biomarkers. This review may help understand how these small molecules play a crucial role in TB pathogenesis and immune response and using them as potential biomarkers to detect tuberculosis.

2. Methods

2.1. Inclusion criteria

Both PubMed and EMBASE electronic databases were screened for relevant studies up to November 2021. Abstracts and full texts were reviewed for information regarding eligibility criteria, excluding abstract-only studies and studies not in English.

2.2. Search strategy

A systematic search of the PubMed and EMBASE databases was performed to extract relevant studies using the following search terms: "(micro RNA OR Mirna OR snRNA) AND (tuberculosis OR tb OR tuberculosis OR tubercular)." The “Zotero” reference manager was used to create a database, and the electronic searches were added to the database. The full text of the qualifying articles was retrieved and studied in detail. The following information was extracted: (a) publication details (authors, year of publication), (b) miRNAs in inflammation and pathogenesis, and (c) miRNAs identified in different clinical samples.

2.3. Method of the review

Two reviewers independently screened citations and abstracts to identify articles potentially meeting the inclusion criteria. Full-text versions were retrieved and individually screened by two reviewers to determine whether they met the inclusion criteria. Disagreements in inclusion criteria were resolved through discussion with a third reviewer.

3. Results

The initial search revealed a total of 965 studies, of which 764 were excluded as those studies were not related to miRNAs in tuberculosis (Fig. 1). We excluded 80 other articles by screening titles and abstracts as they were review articles and bioinformatics analysis. Further, 84 articles were excluded because of the unavailability of full text (abstract only), were cell culture studies, or mice models of tuberculosis infections. Thirty-seven studies were included in the qualitative analysis as these studies described the differential expression of miRNAs in various clinical samples of tuberculosis patients. We further shortlisted 26 articles focusing on miRNAs profiling and divided them into eight sub-groups based on the clinical samples used for miRNAs study in tuberculosis patients. A flow diagram of study screening and selection is shown in Fig. 1.

3.1. Identification of miRNAs in different clinical samples

Screening methods for tuberculosis based on disease biomarkers may help detect subjects in the early stages of the disease. In the last few decades, several studies have been published to identify miRNAs in tuberculosis clinical samples like whole blood, plasma, serum, peripheral blood mononuclear cells (PBMCs), sputum, Pleural fluid, Urine, and Exhaled Breath Condensates (EBCs) collected from patients with active pulmonary tuberculosis. These studies employed unbiased methods like miRNAs microarray analysis or next-generation sequencing techniques or selecting inflammatory and apoptosis-associated candidate miRNAs profiling. The RNA isolation method is crucial in all these techniques, influencing the results. Accumulating evidence suggests that miRNAs are abundantly present in exosomes. Hence, few studies have focused on exosome-vesicles associated with miRNAs isolated from any clinical samples. The identification of miRNAs from clinical samples in active tuberculosis are summarized in Table 1.

3.2. Common miRNAs identified in multiple clinical samples or multiple reports

By establishing differential expression, miRNAs can be used as potential biomarkers in different clinical samples from active tuberculosis patients. A biomarker indicates a normal biological process or a pathogenic process [23]. miRNAs are involved in many pathological processes and can be measured in various clinical samples. In the era of precision medicine, the identification and understanding of the function of specific miRNAs in clinical samples will play an important role. In recent studies, co-regulatory networks of miRNAs and their targeted transcription factor genes were analyzed in various clinical samples of tuberculosis patients [24,25]. Other studies have identified differential expression of miRNAs in patients with tuberculosis compared with...
healthy controls [26]. These studies may help us discover potential miRNAs as tuberculosis biomarkers. This review has screened published research articles that identified differentially expressed miRNAs in different clinical samples and shortlisted some common miRNAs reported in more than one clinical sample in tuberculosis patients. The shortlisted common miRNAs are miR-155, miR-16, Let-7, miR-486, miR-223, miR-99, miR-29, miR-21, miR-193, miR-365, miR-30, miR-20b, miR-146a, miR-31, miR-150 (Table 2).

miR-155 is one of the extensively studied miRNAs found to be up-regulated in serum, plasma, PBMCs, and urine samples of tuberculosis patients [27–30]. However, two reports found decreased levels of miR-155 in plasma and whole blood of tuberculosis patients [31,32]. miR-155 promotes the survival of tuberculosis-specific T cells and affects the adaptive immune response. Another report has suggested that serum miR-155 levels negatively regulated the TB-suppressing activity of natural killer cells. miR-16 was found to be elevated in both plasma and serum samples of tuberculosis patients [20,27]. miR-16 has been shown as a tumour suppressor miRNA for chronic lymphocyte leukaemia [33]. miR-200 was found to be elevated in pleural fluid collected from tuberculosis patients published in two different articles [29,36,37]. miR-200 family members could regulate mesenchymal to epithelial transition by regulating the expression of ZEB1/ZEB2 (zinc-finger- and homeobox-containing transcriptional regulator delta-crystalline enhancer-binding factor) and Smad-interacting protein 1 [38]. Another report suggests that miR-200 can inhibit adenocarcinoma [39]. Let-7 was found to be up-regulated in both serum and plasma samples of tuberculosis patients [20,40,41]. The let-7 family was involved in the pathogenesis by targeting various vital genes. Another report suggested that nuclear factor k beta (NF-kB) inhibits the let-7 family through activation of Lin28B, and the let-7 family directly inhibited the expression of interleukin 6 (IL6) [42]. miR-486 was found to be up-regulated in whole blood and serum samples collected from tuberculosis patients [43,44]. miR-486 may regulate the nuclear factor of activated T-cells 5 (NFAT5) pathway genes [43]. miR-223 was found to be up-regulated in serum and plasma samples of tuberculosis patients compared with healthy controls [20,45]. miR-223 may regulate chemo-attractants including CXCL2, CCL3, and IL-6 in myeloid cells and control leukocyte chemotaxis [46]. miR-99b was elevated in serum, and whole blood samples of tuberculosis patients [27,47]. It was also found to be down-regulated in plasma after the anti-tuberculosis treatment. miR-29a was found to be up-regulated in serum and plasma samples of tuberculosis patients [21,27,47–49]. Interestingly, miR-29a was down-regulated in plasma samples after the treatment of tuberculosis. However, in another report, the levels of miR-29a were found down-regulated in whole blood samples [50]. miR-21 was found to be elevated in serum, whole blood and plasma samples collected from tuberculosis patients compared with healthy controls [21,27,28,51]. miR-21 targets TGF-β signalling pathway genes and regulates the expression [52]. It plays a crucial role in pulmonary fibrosis [53]. However, another report found the down-regulation of miR-21 in plasma samples [54]. miR-193 was up-regulated in PBMCs and serum samples in tuberculosis patients [20,29]. miR-193 plays an essential role in cancer cell proliferation [55]. miR-365 was up-regulated in serum and PBMCs collected from tuberculosis patients [20,22]. miR-365 regulates IL-6 production in macrophages, leading to the immune response in pulmonary tuberculosis [56]. miR-30 was found elevated in plasma, serum, and whole blood samples of tuberculosis patients [20,41,51]. During tuberculosis activation, miR-30 may suppress toll-like receptor/myeloid differentiation factor 88 (TLR/MyD88) activation and cytokine production [57]. miR-20b was found to be up-regulated in serum and whole blood samples collected from patients...
Table 1
Identified miRNAs in clinical samples by profiling and their roles in pathology.

| S. No | Sample Type | Technique Used | miRNAs | Result | Function of miRNAs | Year | References |
|-------|-------------|----------------|--------|--------|--------------------|------|------------|
| 1     | Serum       | miR-361-5p, miR-889, miR-576-3p | miR-361-5p, miR-889, miR-576-3p were up regulated in tuberculosis. | miR-361-5p targets SP-1 transcription factor, a key signaling pathway for IL-10. miR-889 are associated with respiratory system development. miR-576-3p involved in immune system development. miR-93* involves in promoting tumor growth by targeting the tumor suppressor gene Fus1 and integrin-8. miR-29a is a regulator of Wnt signaling pathway genes and lipid metabolism. miR-1249, let-7i, miR-28-3p, miR-103, miR-1178, miR-668, miR-220b, miR-941, miR-151-5p, miR-573, let-7b play role in inflammation. miR-212 regulates the expression of SIRT-1 gene expression. miR-620, miR-320b, miR-151, miR-20b, miR-369-3p, miR-17, miR-20b, miR-369-3p, miR-182, miR-196b, miR-130b*, miR-532-5p, miR-1284, let-7b were down regulated. | 2019 | [58] |
| 1     | Serum       | miR-3125, miR-93*, and miR-29a | miR-3125 was found to be down regulated miR-93*, and miR-29a were up regulated | miR-130b, miR-1284, let-7b play role in inflammation. miR-320b and miR-101 were down regulated. miR-93* involves in promoting tumor growth by targeting the tumor suppressor gene Fus1 and integrin-8. miR-29a is a regulator of Wnt signaling pathway genes and lipid metabolism. miR-1249, let-7i, miR-28-3p, miR-103, miR-1178, miR-668, miR-220b, miR-941, miR-151-5p, miR-573, let-7b play role in inflammation. miR-212 regulates the expression of SIRT-1 gene expression. miR-620, miR-320b, miR-151, miR-20b, miR-369-3p, miR-182, miR-196b, miR-130b, miR-1284 regulate cancer cell proliferation. miR-17-5p and miR-423-5p regulate cell proliferation. miR-20b-5p regulates wound healing process. miR-166b inhibits proliferation and induces apoptosis. miR-516b, miR-486-5p and miR-376c target nuclear factor of activated T-cells 5 and regulate inflammation. Let7e, miR-146a, miR-16, miR-223 modulates inflammation. miR-148a regulates B cell tolerance and autoimmunity. miR-192, miR-193a-5p, miR-25, miR-365, miR-451, miR-532-5p, miR-590-5p, miR-660, miR-885-5p, miR-223*, miR-30e regulate cancer cell proliferation and invasion. | 2014 | [43] |
| 1     | Serum       | miR-196b, miR-516b, miR-486-5p and miR-376c | miR-196b, miR-516b, miR-486-5p and miR-376c were up regulated | miR-16, miR-21, miR-21b, miR-370-3p, miR-140-5p, miR-148b-3p, miR-92a-3p, miR-16 were up regulated. miR-516b, miR-486-5p and miR-376c target nuclear factor of activated T-cells 5 and regulate inflammation. Let7e, miR-146a, miR-16, miR-223 modulates inflammation. miR-148a regulates B cell tolerance and autoimmunity. miR-192, miR-193a-5p, miR-25, miR-365, miR-451, miR-532-5p, miR-590-5p, miR-660, miR-885-5p, miR-30e regulate cancer cell proliferation and invasion. | 2013 | [20] |
| 1     | Serum       | miR-17-5p, miR-20b-5p, and miR-423-5p | miR-17-5p, miR-20b-5p, and miR-423-5p were up regulated | miR-17-5p and miR-423-5p regulate cell proliferation. miR-20b-5p regulates wound healing process. miR-166b inhibits proliferation and induces apoptosis. miR-516b, miR-486-5p and miR-376c target nuclear factor of activated T-cells 5 and regulate inflammation. Let7e, miR-146a, miR-16, miR-223 modulates inflammation. miR-148a regulates B cell tolerance and autoimmunity. miR-192, miR-193a-5p, miR-25, miR-365, miR-451, miR-532-5p, miR-590-5p, miR-660, miR-885-5p, miR-30e regulate cancer cell proliferation and invasion. | 2019 | [58] |
| 1     | Serum       | miR-21-5p, miR-92a-3p, and miR-148b-3p, miR-16 | miR-21-5p, miR-92a-3p, and miR-148b-3p, miR-16 were up regulated in tuberculosis. | miR-21-5p, miR-148b-3p regulates cancer cell proliferation. miR-92a-3p regulates p38 MAPK/NFκB pathway. miR-16 plays role as an anti-inflammatory miRNA. miR-378, miR-483-5p, miR-22, miR-92c, miR-320b and miR-101 regulate cancer cell proliferation. | 2017 | [33] |
| 1     | Serum       | miR-378, miR-483-5p, miR-22, miR-92c, miR-320b and miR-101 | miR-378, miR-483-5p, miR-22, miR-92c, miR-320b and miR-101 were down regulated in tuberculosis | miR-378, miR-483-5p, miR-22, miR-92c, miR-320b and miR-101 were down regulated in tuberculosis. Let7e-5p regulates cell proliferation. miR-140-5p inhibits autophagy, miR-140-5p regulates T cell differentiation. miR-1246, miR-2110 regulate cancer cell proliferation. miR-370-3p targets KDR/AKT signalling pathway gene and inhibits vascular smooth muscle cell proliferation. miR-28-3p regulates B cell lymphomas. miR-193-3p regulates TGF-β gene. miR-150 negatively regulates natural killer cells. miR-21 promotes fibrosis. miR-29c targets IFN-γ and regulates immune cells. miR-194 inhibits innate antiviral immunity. | 2013 | [51] |
| 1     | Serum       | miR-378, miR-483-5p, miR-22, miR-92c, miR-320b and miR-101 | miR-378, miR-483-5p, miR-22, miR-92c, miR-320b and miR-101 were down regulated in tuberculosis | miR-378, miR-483-5p, miR-22, miR-92c, miR-320b and miR-101 regulate cancer cell proliferation. | 2019 | [40] |
| 2     | Whole Blood | hsa-miR-150, hsa-miR-21, hsa-miR-29c and hsa-miR-194 | miR-150 was down regulated and miR-21, miR-29c, miR-194 were up regulated in tuberculosis. | miR-150 negatively regulates natural killer cells. miR-21 promotes fibrosis. miR-29c targets IFN-γ and regulates immune cells. miR-194 inhibits innate antiviral immunity. miR-1 regulates cancer cell proliferation. miR-155 regulates the adaptive immune response. | 2015 | [21] |
| 2     | Whole Blood | miR-1, miR-155, miR-31, miR-146a, miR-10a, miR-125b, miR-150 and miR-29 | miR-1, miR-155, miR-31, miR-146a, miR-10a, miR-125b, miR-150 were up regulated in tuberculosis. | miR-1, miR-155, miR-31, miR-146a, miR-10a, miR-125b, miR-150 were up regulated in tuberculosis. | 2016 | [31] |
| S. No | Sample Type | Technique Used | microRNAs | Result | Function of miRNAs |
|-------|-------------|----------------|-----------|--------|--------------------|
|       |             |                |           |        |                    |
| 3     | Plasma      | miR-182, miR-355, miR-15b*, miR-340, and miR-144 | miR-182, miR-355, miR-15b*, miR-340 were down regulated and miR-144 was up regulated | miR-150 negatively regulates natural killer cells. miR-29c targets IFN-γ and regulates immune cells. | 2012 [85] |
|       |             | miR-26a, miR-29a, and miR-142-3p | miR-26a, miR-29a, and miR-142-3p were down regulated | miR-182, miR-355, miR-15b, miR-340, miR-144 regulate cancer cell proliferation. | 2013 [50] |
|       |             | miR-1197, miR-1268b, miR-1275, miR-1299, miR-146a-3p, miR-150-3p, miR-30a-3p, miR-315a, miR-342-3p, miR-3679-5p, miR-4407, miR-449a, miR-451b, miR-503-5p, miR-505-3p, miR-618, miR-652-3p, miR-652-5p, miR-674-3p, miR-674-5p, miR-708-3p, miR-708-5p, miR-874-3p, miR-874-5p, miR-876-3p, miR-877-3p, miR-92a-1-5p, miR-92a-3-5p, miR-941 | miR-1197, miR-1268b, miR-1299, miR-30a-3p, miR-342-3p, miR-449a, miR-451b, miR-503-5p, miR-629-5p, miR-6513-5p, and miR-941 were up regulated. miR-503-5p were up regulated and miR-21-5p, miR-99b-5p, miR-29a-5p, miR-223-5p, miR-221-3p were down regulated. | miR-125b regulates EMT. miR-146a regulates IL-6 production and inflammation. miR-142 regulates TIMP-1 expression which regulates MMP9 expression. miR-877-5p targets SSK7D and regulates myofibroblast differentiation. miR-20 helps in the cardiac development. miR-26a helps the cellular development, growth, apoptosis and metastasis. miR-106a, miR-191, miR-486, miR-3128, miR-1468, miR-3201, miR-8084 were down regulated | 2018 [51] |
|       |             | miR-26a, miR-29a, and miR-142-3p | miR-26a, miR-29a, and miR-142-3p were down regulated | miR-125b regulates EMT. miR-146a regulates IL-6 production and inflammation. miR-142-3p regulates mesenchymal cells differentiation and proliferation. | 2018 [51] |
|       |             | miR-1197, miR-1268b, miR-1299, miR-146a-3p, miR-150-3p, miR-30a-3p, miR-315a, miR-342-3p, miR-3679-5p, miR-4407, miR-449a, miR-451b, miR-503-5p, miR-505-3p, miR-618, miR-652-3p, miR-652-5p, miR-674-3p, miR-674-5p, miR-708-3p, miR-708-5p, miR-874-3p, miR-874-5p, miR-876-3p, miR-877-3p, miR-92a-1-5p, miR-941 | miR-1197, miR-1268b, miR-1299, miR-30a-3p, miR-342-3p, miR-449a, miR-451b, miR-503-5p, miR-629-5p, miR-6513-5p, and miR-941 were up regulated. miR-503-5p were up regulated and miR-21-5p, miR-99b-5p, miR-29a-5p, miR-223-5p, miR-221-3p were down regulated. | miR-125b regulates EMT. miR-146a regulates IL-6 production and inflammation. miR-150 positively regulates natural killer cells. miR-142-3p regulates mesenchymal cells differentiation and proliferation. | 2019 [44] |
|       |             | miR-20a, miR-20b, miR-26a, miR-106a, miR-191, miR-486, miR-3128, miR-1468, miR-3201, miR-8084 | miR-20a, miR-20b, miR-26a, miR-106a, miR-191, miR-486 were up regulated and miR-3128, miR-1468, miR-3201, miR-8084 were down regulated | miR-125b regulates EMT. miR-146a regulates IL-6 production and inflammation. miR-150 positively regulates natural killer cells. miR-142-3p regulates mesenchymal cells differentiation and proliferation. | 2019 [44] |
| 4     | PBMCs       | miR-20c, miR-193a-3p, miR-595, miR-432, miR-155, miR-9, miR-141, miR-32, miR-29b, miR-152, miR-144 | miR-20c, miR-193a-3p, miR-595, miR-432, miR-155 and miR-9 were up regulated and miR-141, miR-32, miR-29b, miR-152, miR-144 were down regulated | miR-125b regulates EMT. miR-146a regulates IL-6 production and inflammation. miR-10 regulates TGF-β signaling pathway genes. miR-125b regulates EMT. miR-150 negatively regulates natural killer cells. miR-29c targets IFN-γ and regulates immune cells. miR-182, miR-355, miR-15b, miR-340, miR-144 regulate cancer cell proliferation. miR-26a regulates cancer cell proliferation. miR-29a is a regulator of Wnt signaling pathway genes and lipid metabolism. miR-142-3p regulates mesenchymal cells differentiation and proliferation. | 2012 [85] |

(continued on next page)
with tuberculosis [44,58]. However, published evidence suggested that miR-20b alleviates the inflammatory response in the tuberculosis mice model [59]. Another report showed the down-regulation of miR-20b in serum samples collected from tuberculosis patients [54]. miR-146a is also extensively studied miRNAs found to be down-regulated in plasma and whole blood samples collected from tuberculosis patients [20,31,47,51]. miR-31 was found to be down-regulated in whole blood and PBMCs samples collected from patients with tuberculosis [31,60]. According to another report, miR-31 was up-regulated in asthmatic patients [61]. miR-150 was down-regulated in the whole blood sample collected from patients with tuberculosis [21,31]. The report suggests that miR-150 plays an important role in B cell development [62]. However, the identified miRNAs are yet to be validated in all the clinical samples independently.

The discrepancies in the expression of miR-155, miR-29a, miR-21, and miR-20b in different clinical samples might be because of many reasons those influence the outcome of miRNA analysis [63-65]. These may include differences in the time of sample collection, comorbidities, and heterogeneity in the population studied. Other than this, the normalization methods used by different reports are different, and the effect of drug treatment on miRNA response is still unclear. Hence, a different set of subjects may give different expression patterns. Furthermore, different acquisition platforms and data-analysis pipelines used for miRNA quantification can influence the study outcome.

To overcome these issues, we reviewed articles showing the role of these miRNAs in the pathogenesis of tuberculosis. These miRNAs showed the potential role associated with the expression pattern reported in maximum articles. Hence, we precisely focused on the expression pattern of miRNAs reported in maximum articles.

### 3.3. miRNAs as potential biomarkers of tuberculosis

The human genome may encode more than two thousand functional miRNAs, which regulate most protein-coding genes. Interestingly, one miRNA can target multiple genes, and multiple miRNAs can regulate one gene [66]. According to various reports, miRNAs can regulate gene expression involved in the innate or adaptive immune pathways upon Mtb infection in the host [26]. Hence, knowing their association with any immune response, specific miRNAs can be used as a potential diagnostic or prognostic biomarker for tuberculosis. We reviewed the role of the miRNAs in the pathogenesis of tuberculosis. The shortlisted miRNAs including miR-155, miR-146a, miR-21 and miR-9, miR-125b, miR-26-5p, miR-132-3p can regulate innate immune cell activation ([26,54]). Interestingly, miR-155, miR-146a, and miR-21 have been identified in three or more clinical samples collected from tuberculosis patients. However, the rest of the miRNAs were identified in at least one clinical sample. miRNAs including miR-21-5p, miR-146a-5p, miR-20b-5p, miR-223-3p, miR-27b-3p, miR-99b-5p, miR-125-5p, miR-142-3p, miR-144, miR-27a are involved in the regulation of inflammation. miR-21, miR-146, miR-20, miR-223, and miR-99 were identified in two or more clinical samples.

Recent studies have explored the role and regulation of other
Similarly, miRNAs including miR-155, miR-20a-5p, miR-21, Let-7e, rest of the miRNAs were identified in at least one clinical sample. Two or more clinical samples collected from tuberculosis patients. The miR-29a, miR-27b, miR-145 regulate apoptosis during Mtb infection. MiR-155 and miR-20 were identified in the rest of the miRNAs were identified in two or more clinical samples. Mtb infection. miR-155, miR-27a, miR-889, pathological processes (including autophagy and apoptosis) involved during TB infection. miRNAs including miR-155, miR-27a, miR-889, miR-106a, miR-125, miR-142-5p, miR-17, miR-144-5p, miR-20a, miR-23a-5p, miR-26a regulate the activation of autophagy to support the intracellular survival of Mtb. MiR-155 and miR-20 were identified in two or more clinical samples collected from tuberculosis patients. The rest of the miRNAs were identified in at least one clinical sample. Similarly, miRNAs including miR-155, miR-20a-5p, miR-21, Let-7e, miR-29a, miR-27b, miR-145 regulate apoptosis during Mtb infection. MiR-27 and miR-145 were identified in at least one clinical sample, but the rest of the miRNAs were identified in two or more clinical samples. The summary of the targeted genes of the identified miRNAs and their roles in the pathogenesis of tuberculosis is mentioned in Table 3.

4. Discussion

Accumulating evidence suggests that the differential expression of miRNAs may represent the differential pathogenesis of tuberculosis in different cell types. For example, in Mtb, infected macrophages derived from mouse bone marrow showed up-regulation of miR-155 and down-regulated in the infected macrophages derived from peripheral blood mononuclear cells (PBMCs) [15]. Upon Mtb infection, the expression of miR-155 get induced in murine derived macrophages and augment TLR signalling, thereby providing an environment for Mtb multiplication [67]. This promotes Mtb-specific T cells’ survival and enables adaptive immune response. However, serum miR-155 levels show negative regulation of the TB-suppressing activity of NK cells [68]. MiR-155 binds indirectly regulates TNF-α production [69]. Overexpression of let-7e, miR-29a, and miR-886-5p was found in Mtb infected macrophages derived from human monocyte [70]. Interestingly, target prediction analysis reveals that important apoptosis mediator caspases 3 and 7 are potential targets of let-7e and miR-29a. miRNAs profiling in Mtb infected human macrophages showed downregulation of miR-155, miR-146a, miR-145, miR-222, miR-27a, and miR-27b [71,72]. miR-145 is a pro-apoptotic miRNA found to be down-regulated, in line with a suppressed virulent Mtb strain to induce apoptosis [73]. miR-222, miR-27a, and miR-27b play crucial roles in controlling inflammatory response and lipid metabolism. Mtb was infected in human monocytes, and a miRNA expression profile was performed, where nine miRNAs including miR-30a, miR-30e, miR-155, miR-1275, miR-3665, miR-3178, miR-4484, miR-4668-5p, and miR-4497 were found to be differentially expressed [74]. MiR-30a is activated by the TLR pathway and regulates the expression of insulin growth factor (IGF) pathway associated genes and helps in the modulation of cell differentiation, proliferation, and apoptosis [75]. The IGF associated genes have been associated with LPS and pro-inflammatory cytokines production in

### Table 2

| S. No | miRNAs | Remarks   | Sample type | References |
|-------|--------|-----------|-------------|------------|
| 1     | miR-155 | Up regulated | Serum [27] |            |
|       |        |           | Plasma [28] |            |
|       |        |           | PBMCs [29] |            |
|       |        |           | Urine [30] |            |
| 2     | miR-16  | Up regulated | Serum [20,32,90] |          |
|       |        |           | Plasma [34] |            |
| 3     | miR-200 | Up regulated | PBMCs [29] |            |
|       |        |           | Pleural fluid [36,88] |          |
| 4     | Let-7 family | Up regulated | Serum [20,40] |          |
| 5     | miR-486 | Up regulated | Plasma [41] |            |
|       |        |           | Serum [43] |            |
|       |        |           | Whole Blood [44] |          |
| 6     | miR-223 | Up regulated | Serum [20] |            |
|       |        |           | Plasma [47] |            |
| 7     | miR-99  | Up regulated | Serum [27] |            |
|       |        |           | Plasma [47] |            |
| 8     | miR-29  | Up regulated | Serum [27,91] |          |
|       |        |           | Whole Blood [21] |          |
|       |        |           | Plasma [34,47] |          |
| 9     | miR-21  | Up regulated | Serum [27,90] |          |
|       |        |           | Whole Blood [21] |          |
|       |        |           | Plasma [28] |            |
| 10    | miR-193 | Up regulated | Serum [20] |            |
|       |        |           | PBMCs [29] |            |
| 11    | miR-365 | Up regulated | Serum [20] |            |
|       |        |           | PBMCs [22] |            |
| 12    | miR-30  | Up regulated | Serum [20] |            |
|       |        |           | Whole Blood [92] |          |
|       |        |           | Plasma [41] |            |
|       |        |           | Plasma [58] |            |
| 13    | miR-20  | Up regulated | Serum [20] |            |
|       |        |           | Whole Blood [44] |          |
| 14    | miR-146 | Down regulated | Serum [20] |            |
|       |        |           | Whole Blood [31,92] |          |
|       |        |           | Plasma [47] |            |
| 15    | miR-31  | Down regulated | Whole Blood [31] |          |
|       |        |           | PBMCs [60] |            |
| 16    | miR-150 | Down regulated | Whole Blood [21,31,92] |          |

### Table 3

| S. No | Function             | miRNAs       | Targeted Gene | References |
|-------|----------------------|--------------|---------------|------------|
| 1     | Innate Immune        | miR-155     | SHIP1 and TAB2 | [93]       |
|       | response              | miR-146a    | IRAK-1/TRA2-F | [94]       |
|       |                      | miR-21      | PDCD4         | [95]       |
|       |                      | miR-9       | NFKB1         | [96]       |
|       |                      | miR-125b    | ERK1          | [97]       |
|       |                      | miR-26-5p   | KLF4          | [98]       |
|       |                      | miR-132-3p  | TLR           | [99]       |
| 2     | Regulation of       | miR-21-5p   | TLR4          | [100]      |
|       | inflammation         | miR-146a-5p | TRAF-6        | [101]      |
|       |                      | miR-20-5p   | NLRP3         | [102]      |
|       |                      | miR-223-3p  | NFI A         | [103]      |
|       |                      | miR-27b-3p  | Bag2          | [104]      |
|       |                      | miR-99b-3p  | TNF-a and TNRFSF-4 | [105] |
|       |                      | miR-125-5p  | TNF-a         | [106]      |
|       |                      | miR-142-3p  | N-Wasp        | [107]      |
| 3     | Autophagy            | miR-155     | Rheb          | [109]      |
|       |                      | miR-27a     | Cacna2d3      | [110]      |
|       |                      | miR-889     | TWEAK         | [111]      |
|       |                      | miR-106a    | ULK1, ATG7, ATG16L1 | [112] |
|       |                      | miR-125     | DRAM2         | [113]      |
|       |                      | miR-142-5p  | ATG16L1       | [114]      |
|       |                      | miR-17      | ATG7          | [115]      |
|       |                      | miR-144-3p  | ATG4a         | [116]      |
|       |                      | miR-20a     | ATG7 and ATG16L1 | [117] |
|       |                      | miR-22a-5p  | ATG16L1/TLR2/MyD88/NF-κB | [118] |
|       |                      | miR-26a     | KLF4          | [98]       |
|       |                      | miR-20a-5p  | JNK2          | [120]      |
|       |                      | miR-27b     | Bag2          | [104]      |
|       |                      | miR-145     | cIAP1         | [121]      |
|       |                      | Let-7e      | Caspase 3     | [122]      |
|       |                      | miR-29a     | Caspase 7     | [123]      |
|       |                      | miR-21      | PI3/AKT/NFκB  | [124]      |
human macrophages [77]. miR-3178 is known to target TNF receptor-associated factor 3 (TRAF 3) genes and ameliorates inflammation in gastric epithelial cells [78]. Bioinformatics analysis of miR-4484 suggests that the microRNA targets TGF-β and other Wnt/β-catenin signalling pathway-associated genes regulates apoptosis and is involved in collagen regulation related genes [79]. Another miRNA, miR-4668-5p, also targets TGF-β pathway-related genes and is involved in allergic diseases [80]. Other reports suggest that miR-144 expresses in T cells of active tuberculosis patients [81]. The up-regulation of miR-144 reduces T cell proliferation and inhibits the secretion of INF-γ and TNF-α.

Many research groups are identifying the detailed role of these differentially expressed miRNAs in the pathogenesis of tuberculosis. These studies may provide a deep understanding of tuberculosis pathogenesis and provide a good foundation for developing reliable biomarkers for the diagnosis.

However, the expression pattern of miRNAs ultimately depends on the study design. One miRNA may be differentially expressed in one study set, and the same study may have used the same miRNA as a housekeeping gene. Similarly, one miRNA may be differentially expressed in certain disease conditions, and the same miRNA may also have shown differential expression in healthy controls in other studies.

The current article has focused on differentially expressed miRNAs in more than one clinical sample with the same expression pattern. However, a larger population size is required in different studies to establish miRNAs as potential biomarkers for tuberculosis. The diagnostic odds ratio of two oppositely expressed miRNAs may provide more accurate results as a diagnostic marker.

5. Conclusion

Tuberculosis remains one of the deadliest infectious diseases in the world. The causative agent, *Mycobacterium tuberculosis*, regulates the host defence system to survive and replicates through various pathways. In recent studies, the role of miRNAs in the innate and adaptive immune responses upon Mtb infection has been explored. miRNAs are involved in many pathways to alter immune responses by regulating various gene expressions in the host cell. However, there are some limitations in this regard. miRNAs are not entirely gene-specific or disease-specific. Apart from this, innate and adaptive immune response, autophagy and apoptosis are common phenomena in different inflammatory diseases. Same miRNAs can be involved in the pathogenesis of such inflammatory diseases, and it is challenging to separate tuberculosis from other inflammatory diseases based on the miRNAs signatures. Hence, multiple studies have focused on the signatures of shortlisted miRNAs and their expression associated with the pathogenesis of tuberculosis. With this aim, we have reviewed research articles published on differentially expressed miRNAs in clinical samples collected from tuberculosis patients and shortlisted miRNAs consistently shown in more than one clinical sample. This could help in identifying candidate miRNAs for tuberculosis detection.

In this review, we have found common miRNAs shown in various clinical samples in multiple studies. miRNA analysis was performed in the whole blood, serum, plasma, PBMCs, pleural fluid, sputum, urine, and EBC. Most miRNAs are detected in blood samples, which can easily be accessible from tuberculosis patients. Further, these miRNAs are also studied in the pathogenesis pathways of tuberculosis, such as innate and adaptive immune response, autophagy, and apoptosis. However, exploring the specific role of these miRNAs in pathogenesis is ongoing. Moreover, the identified miRNAs need to be validated in more extensive studies using in vitro and in vivo models. As the interest in this field increases, it is essential to identify other miRNAs biomarkers and a specific source of miRNAs in tuberculosis.

Declaration of competing interest

The author has no conflicts of interest to declare.

CRediT authorship contribution statement

Bijay Pattnaik: Writing the original draft, methodology, formal analysis, review & editing, Niharika Pattnaik: Writing - review & editing, Saurabh Mittal: Supervision, Conceptualization, Methodology, Formal analysis, Resources, Anant Mohan, Anurag Agrawal, Randep Guleria: Funding acquisition, Investigation, Project administration, Writing – original Writing - review & editing, Karan Madan: Supervision, Conceptualization, Methodology, Formal analysis, Resources.

Funding

None.

Financial disclosures

None of the authors have any financial disclosures.

Declaration of interest statement

None.

Acknowledgement

None.

References

[1] Y. Su, I. Garcia Baena, A.C. Harde, S.W. Crosby, A.E. Micah, A. Siroka, et al., Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000–17: a financial modelling study [Internet], Lancet Infect. Dis. 20 (8) (2020) 929–942, https://doi.org/10.1016/S1473-3099(20)30124-9. Available from:.

[2] A. Cohen, V.D. Mathiasen, T. Schon, C. Wejebe, The global prevalence of latent tuberculosis: a systematic review and meta-analysis [Internet], Eur. Respir. J. 54 (3) (2019) 1–14, https://doi.org/10.1183/13993003.00655-2019. Available from:.

[3] S. Ahmad, New approaches in the diagnosis and treatment of latent tuberculosis infection, Respir. Res. 11 (2010) 1–17.

[4] Q. Chai, Z. Lu, C.H. Liu, Host defense mechanisms against Mycobacterium tuberculosis [Internet], Cell Mol. Life Sci. 77 (10) (2020) 1859–1876, https://doi.org/10.1007/s00018-019-03153-5. Available from:.

[5] S. Mariotti, M. Pardini, M.C. Gagliardi, R. Teloni, F. Giannoni, M. Fraziano, et al., Dormant *Mycobacterium tuberculosis* fails to block phagosome maturation and shows unexpected capacity to stimulate specific human *T* lymphocytes, J. Immunol. 191 (1) (2013) 274–282.

[6] P. Rohner, B. Ninet, C. Metral, S. Emler, R. Auckenthaler, Evaluation of the MB/ BacT system and comparison to the BACTEC 460 system and solid media for isolation of mycobacteria from clinical specimens, J. Clin. Microbiol. 35 (12) (1997) 3127–3131.

[7] D.A. Geleta, Y.C. Mengerss, A.N. Gudeta, G.T. Akalu, M.T. Debele, K.D. Tulu, Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility Clinical microbiology and vaccines [Internet], BMC Microbiol. 15 (1) (2015) 1–6, https://doi.org/10.1186/s12866-015-0566-6. Available from:.

[8] Y. Tang, L. Yin, S. Tang, H. Zhang, J. Lan, Application of molecular, microbiological, and immunological tests for the diagnosis of bone and joint tuberculosis, J. Clin. Lab. Anal. 32 (2) (2018) 1–7.

[9] E. Mortaz, M.R. Manjedi, A. Abedini, S. Matroodi, A. Kiani, D. Soroush, et al., Common features of tuberculosis and sarcoidosis, Int. J. Mycobacteriol. 5 (Suppl 1) (2016) S240–S241, 2017/01/04.

[10] N. Gupta, G. Singh, M. Rana, Histopathological yield in different types of bronchoscopic biopsies in proven cases of pulmonary tuberculosis, Indian J. Pathol. Microbiol. 58 (4) (2015) 439–442.

[11] T. Yang, B. Ge, miRNAs in immune responses to Mycobacterium tuberculosis infection, Cancer Lett. 431 (2018) 22–30, 2018/05/29.

[12] R.G. Agarwal, P. Sharma, K.K. Nyati, microRNAs in mycobacterial infection: modulation of host immune response and apoptotic pathways, Immune Netw. 19 (5) (2019) c30, 2019/11/14.

[13] B. Ueberberg, M. Kohns, E. Mayatepek, M. Jacobsen, Are microRNAs suitable biomarkers of immunity to tuberculosis? Mol. Cell Pediatr. 1 (1) (2014) 8, 2015/11/15.
infection of macrophages with Mycobacterium tuberculosis, Cell Microbiol. 14 (10) (2012) 1620-1631, 2012/06/21.

[68] C. Zhang, X. Qiu, J. Jiao, L. Zhang, H. Zhao, et al., The association between serum miR-155 and natural killer cells from tuberculosis patients, Int. J. Clin. Exp. Med. 8 (6) (2015) 9168–9172, 2015/08/27.

[69] X. Li, D. Kong, H. Chen, S. Liu, H. Hu, T. Wu, et al., MiR-155 acts as an anti-inflammatory factor during haemocoagulation-Associated foam cell formation by repressing calcineurin-regulated heat stable protein 1, Sci. Rep. 6 (February) (2016) 1–11.

[70] J. Sharbati, A. Lwin, B. Kutz-Lohroff, E. Kamal, R. Einspanier, S. Sharbati, Integrated microRNA-mRNA-analysis of human myocyte derived macrophages upon Mycobacterium avium subsp. hominissuis infection, PLoS One 6 (5) (2011), e20528, 2011/06/02.

[71] J.A. McGregor, S.D. Choi, microRNAs in the regulation of adipogenesis and obesity, [Internet], Curr. Mol. Med. 11 (4) (2011) 304–316. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21569219.

[72] J.W. Graff, A.M. Dickson, G. Clay, A.P. McCaffrey, M.E. Wilson, Identifying functional microRNAs in macropores with polarized phenotypes, J. Biol. Chem. 287 (26) (2012) 21816-21825.

[73] R. Spizzo, M.S. Nicoloso, L. Lupini, Y. Lu, J. Fogarty, S. Rossi, et al., MiR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells, Cell Death Differ. 17 (2) (2010) 246–254.

[74] K. Das, S. Saikia-palopan, S. Dhandayuthapani, Differential expression of miRNAs by macrophages infected with virulent and avirulent Mycobacterium tuberculosis, Tuberculosis (Edinburgh) 93 (Supplement 2) (2013) S528–S529.

[75] L. Ling, S.H. Zhang, I. Da Zhi, H. Li, Q.K. Wen, G. Li, et al., MicroRNA-30e regulates NF-κB inactivation induced by Mycobacterium tuberculosis infection of macrophages with Mycobacterium avium subsp. hominissuis infection, PLoS One 6 (5) (2011), e20528, 2011/06/02.

[76] L. Chen, J. Zhang, J. Li, Z. Zhang, Z. Zhang, H. Zhao, et al., MicroRNA-21 in human monocyte-derived macrophages infected with Mycobacterium tuberculosis: the association with cytokine production in vitro, Tuberculosis (Edinburgh) 93 (Supplement 2) (2013) S574–S575.

[77] B. Pattnaik et al., Non-coding RNA Research 7 (2022) 16–26.
survival in macrophage cells, Front. Cell Infect. Microbiol. 6 (2016) 134, 2016/11/03.

[118] X. Gu, Y. Gao, D.G. Mu, E.Q. Fu, MiR-23a-5p modulates mycobacterial survival and autophagy during mycobacterium tuberculosis infection through TLR2/MyD88/NF-κB pathway by targeting TLR2, Exp. Cell Res. 354 (2) (2017) 71–77, 2017/03/23.

[119] J. Huang, J. Jiao, W. Xu, H. Zhao, C. Zhang, Y. Shi, et al., MiR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3, Mol. Med. Rep. 12 (5) (2015) 7102–7108, 2015/09/02.

[120] G. Zhang, X. Liu, W. Wang, Y. Cai, S. Li, Q. Chen, et al., Down-regulation of miR-20a-5p triggers cell apoptosis to facilitate mycobacterial clearance through targeting JNK2 in human macrophages, Cell Cycle 15 (18) (2016) 2527–2538, 2016/08/06.

[121] M. Zheng, Z. Wu, A. Wu, Z. Huang, N. He, X. Xie, MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADD-caspase-8 complex in triple-negative breast cancer, Tumor Biol. 37 (7) (2016) 8599–8607.

[122] G. Peng, Y. Yuan, Q. He, W. Wu, B yan Luo, MicroRNA let-7e regulates the expression of caspase-3 during apoptosis of PC12 cells following anoxia/reoxygenation injury [Internet], Brain Res. Bull. 86 (3–4) (2011) 272–276, https://doi.org/10.1016/j.brainresbull.2011.07.017. Available from.

[123] J.L. Mott, S. Kobayashi, S.F. Bronk, G.J. Gores, mir-29 regulates Mcl-1 protein expression and apoptosis, Oncogene 26 (42) (2007) 6133–6140.

[124] B. Zhou, D. Wang, G. Sun, F. Mei, Y. Cai, H. Xu, Effect of miR-21 on apoptosis in lung cancer cell through inhibiting the PI3K/Akt/NF-κB signaling pathway in vitro and in vivo, Cell. Physiol. Biochem. 46 (3) (2018) 999–1008.